This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
How Amedisys (AMED) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Q4 Earnings Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -9.62% and 1.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.
Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.
Centene (CNC) to Provide Better Health Equity in North Carolina
by Zacks Equity Research
Centene (CNC) collaborates with Reinvestment Partners to improve the health of North Carolinians.
Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philips (PHG) Q4 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Philips' (PHG) fourth-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.
Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Up 2.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare
by Zacks Equity Research
Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.
Philips (PHG) Aids Clinicians With New Monitoring Solution
by Zacks Equity Research
Philips (PHG) launches Visual Patient Avatar to help anesthesiologists with situational awareness in operating rooms, boosting their clinical confidence.
Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.
Encompass Health (EHC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
Company News for Jul 27, 2023
by Zacks Equity Research
Companies in The News Are: AMED,SNAP,UNP,WFC
Amedisys (AMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.